DrugBiological
Sotatercept clinical trials
Also written ACE-011, MK-7962 and WINREVAIR®.
- studies test it
- 35
- open now
- 9
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the sotatercept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
35 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 20
- Phase 3
- 6
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 10
Merck Sharp & Dohme LLC (15) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (6) · Celgene (4) · Philipps University Marburg (2) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · University of Alberta (1)
Often tested with
Tested in the same studies.
Selexipag (1) · Riociguat (1) · Lenalidomide (1) · Dexamethasone (1) · Pomalidomide (1)
Studies
Open first, then newest update. How each study uses sotatercept is read from its arms, and is right about nine times in ten.
Testing it · 35
- A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)Not yet recruitingPhase 3Merck Sharp & Dohme LLCNCT07839585Written as Sotatercept
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)RecruitingPhase 4Merck Sharp & Dohme LLCNCT07600723Written as Sotatercept
- A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07646860Written as Sotatercept
- Sotatercept in Pulmonary Arterial HypertensionRecruitingPhase 4University of AlbertaNCT07140484Written as Sotatercept
- Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)RecruitingPhase 2Merck Sharp & Dohme LLCNCT05587712Written as Sotatercept
- Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s SyndromeNot yet recruitingPhase 2Philipps University MarburgNCT07498803Written as Sotatercept
- A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator TherapyRecruitingPhase 4Kazuya HosokawaNCT07356778Written as Sotatercept
- SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial HypertensionNot yet recruitingPhase 2Philipps University MarburgNCT07266519Written as Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)RecruitingPhase 4Amsterdam UMC, location VUmcNCT06658522Written as Sotatercept
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT07218029Written as Sotatercept
- A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)CompletedPhase 2Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT04945460Written as Sotatercept 0.3 mg/kg
- Pulmonary Hypertension: Intensification and Personalisation of Combination RxActive, not recruitingPhase 4Sheffield Teaching Hospitals NHS Foundation TrustNCT05825417Written as Sotatercept
- Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06814145Written as Sotatercept
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 1Massachusetts General HospitalNCT01562405Written as ACE-011
- A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT05818137Written as Sotatercept
- Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)TerminatedPhase 3Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT04811092Written as Sotatercept
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)CompletedPhase 3Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT04896008Written as Sotatercept
- Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial HypertensionCompletedPhase 4Mayo ClinicNCT06409026Written as Sotatercept
- A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)CompletedPhase 1Merck Sharp & Dohme LLCNCT06930664Written as Sotatercept
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06925750Written as Sotatercept
See all 35 studies that test sotatercept →
Given in every arm · 1 — sotatercept is usual care beside what is tested
Codes
What other systems call sotatercept · ClinicalTrials.gg INT005461
- MeSH (NLM) C542017sotaterceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0QI90BTJ37SOTATERCEPTConfirmed FDA, NLM, Wikidata
- Wikidata Q103815273sotaterceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80038SotaterceptOne source FDA
- DrugBank DB12118One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C542017 | sotatercept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0QI90BTJ37 | SOTATERCEPT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q103815273 | sotatercept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80038 | Sotatercept | One source FDA |
| DrugBank | DB12118 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.